Healthcare
Live Price
Offline$0.84
-11.58% today
1Y Change
-79.53%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Catheter Precision, Inc. (VTAK) is a Healthcare stock with listed on AMEX. The stock last traded around $0.84 and down 79.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +95.0%, EPS growth of -138.0%, a dividend yield of 0.0%. What stands out right now is revenue +95.0%, EPS -138.0%, free cash flow +11.0% with operating margin -1727.5% and ROIC -101.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VTAK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTAK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VTAK Max Drawdown
-85.19%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VTAK and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$22.0K
+57.1% YoY
FY Net Income
-$25.1M
+6.7% YoY
Free Cash Flow
-$27.9M
-23.5% YoY
Revenue Growth
+95.0%
EPS Growth
-138.0%
Gross Margin
27.8%
Net Margin
-2086.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 819K | 420K | 442K | 14K | 22K |
| Gross Profit | 756K | 378K | 412K | -147K | -2M |
| Operating Income | -21M | -11M | -78M | -27M | -29M |
| EBITDA | -21M | -11M | -15M | -22M | -26M |
| Net Income | -17M | -17M | -71M | -27M | -25M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 88K | 3M | 4M | 16M | 15M |
| Total Assets | 16M | 28M | 31M | 17M | 21M |
| Total Liabilities | 9M | 16M | 10M | 8M | 7M |
| Shareholder Equity | 7M | 12M | 21M | 9M | 14M |
| Total Debt | 4M | 2M | 372K | 0 | 2M |
| Net Debt | 4M | -1M | -3M | -16M | -13M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
28M
-22.4% YoY
Capital Expenditures
265K
-1458.8% YoY
Free Cash Flow
28M
-23.5% YoY
Key ratios
Gross Margin
27.8%
Operating Margin
-1727.5%
Net Margin
-2086.7%
ROE
-239.5%
Debt / Equity
0.55x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.